Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum
© Ullah et al.; licensee BioMed Central Ltd. 2013
Received: 5 March 2013
Accepted: 12 August 2013
Published: 19 August 2013
Guided migration of chondrogenically differentiated cells has not been well studied, even though it may be critical for growth, repair, and regenerative processes. The chemokine CCL25 is believed to play a critical role in the directional migration of leukocytes and stem cells. To investigate the motility effect of serum- or CCL25-mediated chemotaxis on chondrogenically differentiated cells, mesenchymal stem cells (MSCs) were induced to chondrogenic lineage cells.
MSC-derived chondrogenically differentiated cells were characterized for morphology, histology, immunohistochemistry, quantitative polymerase chain reaction (qPCR), surface profile, and serum- or CCL25-mediated cell migration. Additionally, the chemokine receptor, CCR9, was examined in different states of MSCs.
The chondrogenic differentiated state of MSCs was positive for collagen type II and Alcian blue staining, and showed significantly upregulated expression of COL2A1 and SOX9, and downregulated expression of CD44, CD73, CD90, CD105 and CD166, in contrast to the undifferentiated and dedifferentiated states of MSCs. For the chondrogenic differentiated, undifferentiated, and dedifferentiated states of MSCs, the serum-mediated chemotaxis was in a percentage ratio of 33%:84%:85%, and CCL25-mediated chemotaxis was in percentage ratio of 12%:14%:13%, respectively. On the protein level, CCR9, receptor of CCL25, was expressed in the form of extracellular and intracellular domains. On the gene level, qPCR confirmed the expression of CCR9 in different states of MSCs.
CCL25 is an effective cue to guide migration in a directional way. In CCL25-mediated chemotaxis, the cell-migration rate was almost the same for different states of MSCs. In serum-mediated chemotaxis, the cell-migration rate of chondrogenically differentiated cells was significantly lower than that in undifferentiated or dedifferentiated cells. Current knowledge of the surface CD profile and cell migration could be beneficial for regenerative cellular therapies.
KeywordsChondrogenically differentiated cells Stem cells Cell migration Chemotaxis CCL25 CCR9
Human mesenchymal stem cells (MSCs) hold great promise for tissue regeneration. During tissue repair, MSCs migrate to the sites of injury and participate in the repair process [1, 2]. Stem cell migration not only plays a potential role in cell colonization inside biomaterial scaffolding , but also takes part in the reorganization of matrix . Moreover, the guided migration of MSCs creates a therapeutic environment for bone regeneration . These features emphasize the importance of targeted stem cell migration in tissue-engineering approaches.
Stem cell migration improves the curative ability of diseased tissues via appropriate homing inside injured sites [1, 2, 6]. Previously, it was reported that cell migration and subsequent suitable colonization of progenitor stem cells within injured sites accelerate myocardial regeneration [7, 8], reduce heart damage [9, 10], aid in recovery from spinal-cord injuries , cure nerve damage , and repair cartilage [13, 14]. The MSCs have the potential to migrate through bone marrow endothelium, by using the regulatory mediators of matrix metalloproteinase-2 and tissue-inhibitor metalloproteinase-3 . The administration of allogenic MSCs, whether derived from bone marrow or from adipose tissue, was reported for cellular proliferation, neurogenesis, and takes part in the functional recovery of brain after ischemic stroke . Moreover, clinical trials of using human MSCs for bone fractures, bone defects, and cartilage disorders have been performed [17–19]. The investigation of targeted stem cell migration could be beneficial for tissue regeneration, especially for cartilage restoration. Chondrocytes in the articular cartilage lack innervations and vascularization and have low mitotic potential. Moreover, the chondrocytes have no physical contact to each other and entrapped into extracellular matrix [20–22]. These features make cartilage restoration is a hot issue in case of regeneration.
Autologous chondrocyte transplantation is an established technique for cartilage repair [23–25], which consists of chondrocyte isolation, in vitro dedifferentiation, and transplantation [25–27]. It is established that dedifferentiation is necessary to achieve a high cell number, and it is considered a curative step in such technologies [28–30]. However, massive dedifferentiation of chondrocytes results in loss of the chondrogenic phenotype and formation of primitive multipotent cell types [28–31]. To overcome such shortcomings, chondrogenic maintenance cues such as cytokines, chemokines, and growth factors are required to regulate and control the process of chondrocyte transplantation. The theoretic assumption is that this would increase remedial time and therapeutic cost because of in vivo posttransplantational procedures for chondrogenic differentiation and maintenance. It necessitates the use of such culture techniques and cell types, which not only maintain a chondrogenic-specific phenotype, from the beginning of transplantation, but also proliferate to increase the number of cells.
Therefore, the direct mobilization of endogenous cells and subsequent migration to the point of injury could be a promising approach for cartilage regeneration. In this context, the motility and migratory features of chondrocytes have been characterized . To investigate the migratory effect of serum- or CCL25-mediated chemotaxis on chondrogenic cells, we isolated differentiated cells from compact pellets, after 28 days of chondrogenic differentiation. They maintained the chondrogenic nature for about 14 days in the culture and were able to proliferate. After chondrogenic confirmation, their surface profile and cell-migration ability were examined for serum- or CCL25-mediated chemotaxis.
Present strategies of stem cells transplantation advocate the use of MSCs [23, 33–35], for diverse regenerative application, including cartilage repair [23, 26]. In some cases, the clinical use of MSCs is considered more valuable than autologous chondrocytes transplantation [36, 37], as it requires one less knee surgery, is easy to isolate, has a high proliferative rate, reduces cost, and provides better regenerative efficiency [28, 35, 36]. For instance, the use of magnetized MSCs is the best choice for articular cartilage repair . In such cases, one controversial and basic question needs an answer: which cell type would be more suitable for cartilage regeneration, undifferentiated MSCs or their chondrogenic differentiated progeny? Therefore, we investigated the cell-migration profile of chondrogenically differentiated cells compared with the undifferentiated and dedifferentiated states of MSCs, according to already described formulation and concentration of allogenic serum .
However, allogenic serum has a complex composition [40–42], which is unknown and undefined for some molecular functions. It emphasizes the need for a defined and targeted chemokine, to make the present regenerative strategies more valuable and beneficial for appropriate cell homing. Moreover, chemokines are recognized as an essential factors for diverse cellular process including activation of the central hub of cellular migration via direct or indirect mechanisms and signaling events [39, 43–45], and stimulation of the therapeutic efficiency of regeneration.
Chemotaxis is defined as directional movement of cells toward concentration gradients or chemoattractants, whereas chemokinesis is random cell movement without any chemoattractants . Directional migration of MSCs to the site of injury is controlled by several factors, such as hypoxia and the Rho family of GTPases [47, 48]. Generally, tissue regeneration requires a coordinating and well-regulating cell migration for its restoration in response to different cues like cytokines and growth factors [43, 49]. Apart from this, chemokines play a vital role in a biologic plethora of migration and are considered guided cues for directional and targeted stem cell trafficking [39, 43, 49]. Chemokines enable the activity of migratory processes in hematopoietic and nonhematopoietic cells , navigate the cellular trafficking between tissue compartments, and play a potential role in cell activation, differentiation, survival, and recruitment of leukocytes . In addition, they play a decisive role in mobilization of T lymphocytes during allergenic reactions  and contribute to the complex pathophysiology of asthma by using the coordinating network of cellular activation and signaling web .
Chemokine-based recruitment of MSCs to the point of injury is a promising approach, whereas chemokine (C-C motif) ligand 25 (CCL25) could play a vital role in cell migration [44, 54]. After nerve damage or myocardial infarction, the mutual interactions of chemokines and their receptors mediate the migration of MSCs to injured sites . Obviously, to understand the underlying mechanism would be of interest. In this context, CCL25 has been suggested as a potential chemoattractant for the directional movement of MSCs , and C-C chemokine receptor type 9 (CCR9) is known as a cognate receptor of CCL25 [57, 58]. To check whether the chondrogenic differentiated state of MSCs affects the cell-migration rate, we performed the chemotaxis assay for undifferentiated, chondrogenic differentiated and dedifferentiated cells, by using the chemokine CCL25 . Furthermore, the receptor CCR9 was examined in different states of MSCs, as CCR9 is an established known receptor of CCL25 and plays a decisive role in the targeted migration of stem cells [43, 44, 54].
To cope with the challenges of the growing tissue-engineering industry, we need an appropriate cell source and suitable cell types, which are able not only to migrate to the site of injuries or damage in a well-guided way, but also to facilitate quick regeneration. Our introduced cell types could be valuable and beneficial in this regard.
Materials and methods
Ethics statement and MSC isolation
The study was approved by the institutional ethical committee of the Charité-University Medicine Berlin. Written informed consent was obtained from all participants, as a requirement of the ethical review board. The human MSCs were isolated from iliac crest bone marrow aspirates (n = 3; two men, one women; average age, 52.3 ± 1.5 years) of the healthy donors, who were examined to exclude hematopoietic neoplasms and were histologically diagnosed as normal. The 1-ml aspirate was seeded per T175 cm2 of culture flasks (Becton Dickinson, Heidelberg, Germany). After 72 hours, nonadherent cells and cellular debris were washed out by media exchange, and cultures were further expanded in Dulbecco Modified Eagle Medium (DMEM; Biochrom, Berlin, Germany), supplemented with 10% fetal bovine serum (FBS; Hyclone, Cramlington, UK), 20 mM Hepes buffer (Biochrom), 2 mM L-glutamine (Biochrom), 2 ng/ml human basic-fibroblast growth factor (bFGF; Pepro Tech, London, UK) 100 units/ml penicillin and 100 μg/ml streptomycin (Biochrom), under established conditions. After expansion and subsequent confluences, the cells were detached with trypsin (0.05% 1 mM EDTA), and replated until passage 3.
For chondrogenic differentiation, 2.5 × 105 MSCs were centrifuged (150 g, 5 minutes) to form high-density micromass culture pellets. The chondrogenic differentiation of these pellets was achieved for 28 days with DMEM (4.5 g/L glucose; Biochrom), ITS supplements, 100 nM dexamethasone, 0.17 mM ascorbic acid-2-phosphate, 1 mM sodium pyruvate, 0.35 mM L-proline (all Sigma-Aldrich) and 10 ng/ml transforming growth factor-β3 (TGF-β3; PeproTeck, Hamburg, Germany). The control pellets were cultured in the same medium in the absence of TGF-β3. The medium (500 μl) was changed 3 times per week.
Cell isolation from chondrogenic pellets and dedifferentiation
After chondrogenic differentiation of the pellets for 28 days, cells were isolated with 300 U of collagenase II, 20 U of collagenase P, and 2 mM CaCl2 for 90 minutes at 37°C . Subsequently, some cells were cultured in a monolayer for 14 days in the presence of the chondrogenic differentiation-specific stimulus of TGF-β3, to maintain their chondrogenic nature. Conversely, the chondrogenically differentiated cells were cultured for five passages in the normal MSC expansion medium to accelerate proliferation and to generate dedifferentiated progenitor cells.
Flow-cytometric analysis for cell-surface screening
Fluorescence-activated cell sorting (FACS) analysis was performed not only to characterize the MSCs for their typical specific surface antigens, but also to determine the expression of these antigens in chondrogenic differentiated and dedifferentiated cells. For all experimental cell types, the cells (n = 3) were prepared in the form of a single-cell suspension, then washed with PBS/0.5% bovine serum albumin (BSA; both Biochrom), and centrifuged for 5 minutes at 250 g. The resuspended cells in the cold PBS/0.5% BSA were incubated for 15 minutes on ice with R-phycoerythrin-labeled mouse anti-human CD14, CD34, CD73, CD166, and fluorescein isothiocyanate (FITC)-labeled mouse anti-human CD44, CD45, CD90, and CD105 antibodies. All antibodies were purchased from BD-Pharmingen (Heidelberg, Germany) except CD105, which was purchased from Acris Antibodies (Hiddenhausen, Germany).
After incubation, the cells were centrifuged (250 g, 5 minutes), washed with cold PBS/0.5% BSA, and resuspended in the same buffer before cytometric analysis. To examine the extracellular domain of CCR9 receptor, staining was performed as described earlier but with PE-labeled mouse anti-human CCR9 (R&D Systems, Wiesbaden, Germany). For measurement of the intracellular domain of the CCR9 receptor, one additional step of permeabilization was added. After fixation with 4% paraformaldehyde (Sigma, Germany) for 15 minutes, cells were permeabilized for 10 minutes with FACS permeabilizing solution-2 (Becton Dickinson, Germany) and then processed as described earlier. The propidium iodide (100 μg/ml; Sigma-Aldrich) staining was applied for the exclusion of dead cells and cellular debris, whereas unstained cells were used as a negative control. The single-cell suspension was analyzed with flow cytometry, and CellQuest software (Becton Dickinson) was used for the interpretation and analysis of results.
Migration potential of cells
Migration potential of MSCs, chondrogenic differentiated cells, and dedifferentiated cells were assessed in response to 10% human allogenic serum or CCL25 chemokine (PeproTech, Germany). An already established chemotaxis assay by our group [33, 54, 60], was performed for all cell types with 8-μm pore size polycarbonate membranes in 96-multiwell format ChemoTx plates (Neuroprobe, Gaithersburg, USA). For migration of cells, either 10% allogenic serum or a selected concentration of CCL25 (500 nm, 750 nm, and 1,000 nm)  was applied in triplicate to the lower wells. The 4 × 104 cells for serum and 3 × 104 cells for CCL25 were seeded in the upper wells and incubated for 20 hours at 37°C. Negative controls were performed without chemokine or serum. Migrated cells were fixed in methanol/acetone, stained with hemacolor (Merck, Germany), and counted microscopically with Image J software.
Histology and immunohistochemistry
To examine chondrogenesis, the high-density micromass pellets were embedded in Tissue-Tek with O.C.T compound (Sakura Finetek, Torrance, USA), and then were frozen in liquid nitrogen and cryosectioned (6-μm thickness). For the cartilage-specific proteoglycan examination, these sections were stained with Alcian blue 8GX (Roth, Karlsruhe, Germany) and counterstained with nuclear fast red (Sigma Aldrich). For the deposition and accumulation of collagen type II in the ECM, cryosections (6 μm) were incubated for 1 hour with primary rabbit anti-human type II collagen antibodies (Acris Antibodies). Subsequently, the sections were processed according to the manufacturer’s recommendation with the Envision system peroxidase kit (DAKO, Hamburg, Germany), followed by hematoxylin counterstaining (Merck, Darmstadt, Germany). The stained sections in the control samples were prepared from the chondrogenic control pellets.
To stain the chondrogenic differentiated and dedifferentiated cells, 2 × 105 cells were transferred to each well of the four-well chamber slides (Thermo-scientific, Germany). The cells inside chamber slides were cultured for 3 days under standard conditions to ensure the proper attachment of the cells to the slide surface. For direct staining, the cells were fixed for 5 minutes in already cooled 3.7% formaldehyde in PBS. Subsequently, cells were stained according to the standard procedure, as described for cryosections of the chondrogenic pellets.
RNA isolation and qPCR
For RNA isolation, the MSCs, chondrogenic differentiated, and dedifferentiated cells were mixed with TriReagent (Sigma-Aldrich). While the differentiated chondrogenic pellets [11–17], were first pooled for each individual donor (n = 3) in the 2-ml Eppendorf tube, then the TriReagent was mixed with these pellets and mechanically homogenized with an Ultra-Turrax (IKA, Staufen, Germany). Then 1-bromo-3-chloro-propane (Sigma-Aldrich) was added to all samples, followed by centrifugation (45 minutes, 13,000 g), and the upper phase, being free of proteins, was collected and mixed with an equal amount of ethanol. Subsequently, samples were processed with the RNeasy Mini Kit (Qiagen, Hilden, Germany), according to manufacturer recommendation. The quantity and quality of eluted RNA was ensured with NanoDrop measurements (NanoDrop Products, Wilmington, USA).
For qPCR, cDNA was synthesized from 2.5 μg total RNA by using the iScript cDNA synthesis kit (BioRad, Munich, Germany). The TaqMan qPCR was executed in triplicates in 96-well optical plates on a Mastercycler ep Realplex2 S system (Eppendorf, Hamburg, Germany). The gene-expression assays for typical chondrogenic-specific genes was performed with TaqMan probes and primer sets (Applied Biosystems, Darmstadt, Germany). Quantitative gene expression was analyzed for collagen type 2 A1 (COL2A1; Hs 00264051_m1), SRY (sex- determining region Y)-box-9 (SOX9; Hs 00165814_m1), C-C chemokine receptor type 9 (CCR9; Hs 01890924_s1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905_m1). The expression of COL2A1 and SOX9 genes was normalized to the endogenous GAPDH expression level and calculated with the 2-ΔΔCt formula in percentage of GAPDH expression .
The statistical analysis was performed by using SigmaStat 3.5 software (Systat Software, USA), whereas GraphPad Prism4 (GraphPad Software) was used for drawing graphs. Simple Student t test was used for statistical assessment, and asterisks were assigned in the order P* < 0.05, P** < 0.01, and P*** < 0.001 for statistically significant values, whereas exact P values were mentioned for statistically nonsignificant data sets. Error bars in all figures represent standard error of the mean.
MSC isolation, authentication, and chondrogenic differentiation
Isolation of chondrogenic differentiated cells
Similarly, on the gene level, they showed significantly higher expression of COL2A1 and SOX9 compared with undifferentiated MSCs and unstimulated controls (Figure 2E). After removing the extracellular components, the cultured cells were isolated with trypsinization (after 3 days) and subsequently analyzed for surface antigens. The surface screening showed a reduced expression for CD44, CD73, CD90, CD105, and CD166 antigens (Figure 2F; see Additional file 3: Figure S2) compared with undifferentiated MSCs (Figure 1H), indicating that MSCs reduce their expression for above-surface CD epitopes on chondrogenic differentiation. This statement is further confirmed by the comparative flow-cytometric analysis of surface antigens for three independent donors, in chondrogenically differentiated cells compared with undifferentiated and dedifferentiated cells (see Additional file 2: Figure S5).
Dedifferentiation of chondrogenic differentiated cells
Migration of undifferentiated, chondrogenic differentiated, and dedifferentiated cells in response to serum-mediated chemotaxis
In conclusion, the percentage comparison relative to total cell number (40 × 103) revealed about 33%, 84%, and 85% cell migration for the chondrogenic differentiated, undifferentiated, and dedifferentiated states of MSCs, respectively (Figure 4J). This is in line with the statement that mature chondrocytes have relatively low migration potential in vivo for cartilage repair, because of its inherent architectural nature [20, 22]. Allogenic 10% serum-mediated chemotaxis recruited relatively more cells for the undifferentiated (84%) and dedifferentiated states (85%), compared with the chondrogenic differentiated state (33%) of MSCs.
Migration of undifferentiated, chondrogenic differentiated, and dedifferentiated cells in response to CCL25-mediated chemotaxis
To show an obvious comparative representation of cell migration in different states of MSCs, percentage quantification analysis was performed. The percentage quantification assessment with Image J software revealed a cell migration of about 12% for the chondrogenic differentiated state, about 14% for the undifferentiated state, and about 13% for the dedifferentiated state of MSCs of a total 30 × 103 cells (Figure 5J) in response to CCL25-mediated chemotaxis at a concentration of 1,000 nM chemokine.
In conclusion, chondrogenically differentiated cells showed a low migration potential compared with undifferentiated MSCs and dedifferentiated cells in response to serum-mediated chemotaxis. The reason for this low migration potential of chondrogenic differentiated cells may be hidden in the loss/modification of migration-specific receptors to serum, during differentiation. Conversely, chondrogenically differentiated cells had almost equally migrated (12%) compared with undifferentiated MSCs (14%) and dedifferentiated cells (13%) in response to CCL25-mediated chemotaxis. This enhances the value of CCL25 as a guided chemokine for cartilage repair, as its chemotactic activity is not influenced by the differentiated or undifferentiated nature of the cells. Alternatively, the receptors taking part in the CCL25-mediated chemotaxis, perhaps had not lost/modified their expression, during chondrogenic differentiation. However, CCL25 controls cellular trafficking irrespective of the cell architectural nature and the differentiated state, so it is important to investigate CCL25 as a migratory cue, in a broad spectrum, as the concentration of CCL25 (1,000 nM) was maintained similarly for undifferentiated, differentiated, and dedifferentiated states of MSCs.
Why did the chondrogenic differentiated state show an almost equal rate of cell migration in CCL25-mediated chemotaxis compared with undifferentiated and dedifferentiated states of MSCs? CCR9, a binding receptor of CCL25 chemokine, was investigated to determine the role in guided cell migration.
Analysis of CCR9, a cellular receptor of CCL25 chemokine
For quantitative measurement, flow-cytometric analysis was performed to examine the expression level of CCR9 receptor. However, CCR9 receptor has two distinct domains called extracellular and intracellular; thus flow-cytometric analysis was performed to screen all states of MSCs for its two domains. After analysis, their expression was quantitatively expressed in the form of averages, along with standard deviations (n = 3); here the representative bars are divided to specify a minimum or maximum expression. For undifferentiated (Figure 6C) and chondrogenic differentiated (Figure 6F) states of MSCs, the expression of extracellular and intracellular domains was almost similar and about 10% for each domain, whereas for the dedifferentiated state of MSCs, the expression of extracellular and intracellular domains was about 18% and 5%, respectively (Figure 6I). The detailed histogram plots for extracellular and intracellular domains of CCR9 receptors are in the form of supplemental files, for undifferentiated, chondrogenic differentiated, and dedifferentiated states of MSCs (see Additional file 5: Figure S4).
The expression level of CCR9 was almost homogeneous for extracellular (10%) and intracellular (10%) domains, and collectively about 20% for each undifferentiated and chondrogenic differentiated state of MSCs, and a bit higher, about 23%, for their dedifferentiated state (Figure 6C, F, and I). On a molecular level, the qPCR analysis was performed for CCR9 gene expression, which showed significantly upregulated expression for the chondrogenic differentiated state compared with undifferentiated and dedifferentiated states of MSCs (Figure 6J). Here, the protein and gene level expression of CCR9 confirms the presence of receptor in undifferentiated, differentiated, and dedifferentiated states of MSCs.
Guided stem cell migration is a vital approach for cell recruitment to the point of injury or damage. For cartilage regeneration, the endogenous mobilization of chondrogenic cells and subsequent migration could be a promising approach. In this context, the in vivo model remains to be proven; however, we performed some primary experiments in vitro for guided cell migration of chondrogenic differentiated cells, a step toward the search for the right cells for the job. Cartilage tissue is a combination of progenitor and differentiated cell types, such as chondroblasts, chondrocytes, and dedifferentiated cells [20, 29, 32]. Therefore, in the current study, we analyzed the chemotactic ability of undifferentiated, chondrogenic differentiated, and dedifferentiated states of MSCs with serum- or CCL25-mediated chemotaxis. Moreover, the surface profile of CD markers was investigated to screen and specify the chondrogenic differentiated state on the basis of typical MSC antigens. The flow-cytometric analysis revealed a low level of expression for CD44, CD73, CD90, CD105, and CD166 antigens in the chondrogenic differentiated state compared with undifferentiated and dedifferentiated states of MSCs, suggesting that chondrogenically differentiated cells reduce their expression for these surface antigens. In addition, these surface antigens are good characterizing markers for chondrogenically differentiated cells and their progeny, and in line with previously published reports, recommending the use of such surface markers for identification of chondrogenic cells [65, 66].
Chondrogenically differentiated cells were assessed for cell migration in response to 10% allogenic serum-mediated chemotaxis  or an established concentration of 500 nM, 750 nM, and 1,000 nM CCL25-mediated chemotaxis [44, 54]. In serum-mediated chemotaxis, we observed a significant decrease in recruited cells for the chondrogenic differentiated state (33%) compared with undifferentiated (84%) and dedifferentiated states (85%) of MSCs. We would recommend the use of chondrogenically differentiated cells for therapeutic repair of cartilage, as they have active signaling pathways, chondrogenic character, and biological paradigms of the differentiated state. For fast-track regeneration, the cartilaginous nature and chemokinetic ability of chondrogenically differentiated cells could be a beneficial asset.
For migration, serum is considered a very good chemoattractant for recruitment of cells; however, its composition is very complex, and its role as yet unknown in several biologic functions [40–42]. Therefore, we applied CCL25 for cell recruitment, a well-known chemokine for targeted stem cell migration [44, 54]. Here, we noticed negligibly low migration potential for chondrogenically differentiated cells compared with serum-mediated chemotaxis.
In serum-mediated chemotaxis, we blame the inherent architectural ability of the chondrogenic differentiated state of MSCs for its limited cell migration. As chondrocytes have limited mitotic potential, lack of innervations and vascular supply, and are entrapped in the extracellular matrix, almost no physical contact with each other and restricted migration potential to the point of injury in vivo[20–22]. The CCL25-mediated chemotaxis has recruited 14%, 13%, and 12% of cells, respectively for undifferentiated, dedifferentiated, and chondrogenic differentiated states of MSCs. Here, the migration rate of chondrogenically differ-entiated cells was almost similar to the differentiated or undifferentiated states of MSCs. Perhaps the activation of some receptors and signaling in the chondrogenic differentiated state is the cause of this higher chemotactic ability. In this way, CCL25-mediated chemotaxis favors guided cellular trafficking, and we recommend the use of CCL25 as a migratory cue in regenerative applications. This especially highlights the significant use of chondrogenically differentiated cells for cartilage restoration because they have almost the same migration potential compared with the undifferentiated and dedifferentiated states of MSCs. The collective use of CCL25 chemokine and chondrogenic differentiated states of MSCs could be more beneficial for cartilage regeneration, possibly because of their active signaling, so the use of chondrogenically differentiated cells for cartilage repair could be fruitful.
We propose that chemotactic signals and inflammatory response from injured sites could induce cellular mobilization and create an intermediate pore sizes for subsequent movement of cells to the injured sites. Our suggestion is in line with the reports that inflammation plays a critical role in the regeneration of cartilage tissue [32, 67–70].
Cytokine- and especially chemokine-based migration is a crucial step for in vivo regenerative application [43, 71]. In this context, CCL25/CCR9 is a chemokine/receptor pair and plays a key regulative role in stem cell migration [57, 58]. In our study, the immunohistochemical analysis was performed for the assessment of CCR9 receptor, which showed almost uniform staining for undifferentiated, differentiated, and dedifferentiated states of MSCs, indicated the presence of receptors in these states. However, we have not used the positive controls for immunohistochemical staining of CCR9 receptor, which is a study limitation. For quantitative analysis, flow-cytometric analysis was performed to measure the expression of the extracellular and intracellular domains of the CCR9 receptor. It has been reported that intracellular signaling is required for CCL25 activation and stimulation of chemoattractant ability [45, 72]. The expression of extracellular and intracellular domains of CCR9 collectively revealed about 20% expression for the undifferentiated and chondrogenic differentiated states, but about 23% expression for the dedifferentiated state of MSCs.
On the molecular level, we analyzed all states of MSCs for CCR9 gene expression by performing qPCR, to identify the normalized amount of receptor to GAPDH. Gene analysis showed significantly upregulated expression of CCR9 in the chondrogenic differentiated state compared with the undifferentiated and dedifferentiated states of MSCs. To correlate the protein- and gene-level expression, we propose that any apparent observational change in the protein and gene level of the CCR9 receptor could be the cause of posttranscriptional and posttranslational level modification. In some cases, the protein-level expression of CCR9 does not correlate with mRNA level expression, and such noncorrelation of CCL25/CCR9 has been reported in mucosal immune systems on protein and gene levels , and favors our speculation about posttranslational modification. Furthermore, it also supports the Monte Carlo effect, a hypothesis drawn about the biological importance that the level of mRNA expression is not always directly correlated with the protein expression . In addition, the chemotactic ability of CCL25 not only is the result of a cellular receptor of CCR9, but also is receiving signals from other receptors and signaling cascades for activation, stimulation, and cellular migration .
The current study generated the knowledge of the comparative surface CD profile, chemotaxis, and migration potential for undifferentiated, chondrogenic differentiated, and dedifferentiated states of MSCs. To understand the molecular mechanisms of migration in different states of MSCs could be valuable to identify the potential targets for wound healing, damage repair, and regeneration.
The chemokines, cytokines, and growth factors in consequence of inflammation facilitate cells homing to the site of injury and improve tissue regeneration . These regenerative strategies emphasize the importance of targeted and guided chemotaxis for cell migration. Therefore, the chondrogenically differentiated cells were investigated for their chemotactic ability. In this context, chondrogenic pellets were generated from MSCs by using chondrogenic differentiation medium for 28 days. The chondrogenic nature of the pellets was confirmed by proteoglycan-specific Alcian blue staining, cartilage-specific collagen type II staining, and significantly upregulated cartilage-specific genes COL2A1 and SOX9. Then differentiated cells were isolated from the intact chondrogenic pellets with enzymatic cues consisting of 300 U of collagenase II, 20 U of collagenase P, and 2 mM CaCl2. After successful isolation, the differentiated cells were again verified for chondrogenic features, and they were positive for Alcian blue staining, collagen type II staining, and showed an upregulated expression of COL2A1 and SOX9.
Afterward, the chondrogenically differentiated cells were washed with PBS, and extracellular matrix was removed; then their surface was analyzed for surface CD antigens. The surface profile of chondrogenically differentiated cells showed a positive expression of CD44, CD73, CD90, CD105, and CD166, but notably this expression was about 40% to 50% lower than that in undifferentiated and dedifferentiated states of MSCs. In serum-mediated chemotaxis, the number of migrated cells was significantly lower for the chondrogenic differentiated state (33%) compared with the undifferentiated (84%) and dedifferentiated (85%) states of MSCs, of a total 40 × 103 cells. In CCL25-mediated chemotaxis, the number of migrated cells was almost the same for the chondrogenic differentiated state (12%) compared with undifferentiated (14%) and dedifferentiated states (13%) of MSCs, of a total of 30 × 103 cells.
The expression of CCR9 was examined with immunohistochemistry and flow-cytometric analysis, which confirmed the presence of CCR9 in undifferentiated, differentiated, and dedifferentiated states of MSCs. On the molecular level, the expression of CCR9 was significantly upregulated in the chondrogenic differentiated state compared with the undifferentiated and dedifferentiated states of MSCs. We propose that CCL25-mediated chemotaxis is influenced by the expression of CCR9 and stimulates guided cell migration in all states of MSCs. Cell migration as a result of mutual interaction of CCL25 and CCR9 has already been studied , and supports our conclusive message of guided chemotaxis. Moreover, the coupling interactions between CCL25 and CCR9 induce cell migration in porcine mucosal tissue and in the immune system during fetal development [57, 58].
The in vivo migration of chondrogenically differentiated cells remains to be proven; however, in vitro oriented cell migration and homing study could provide valuable arguments in this direction for further investigation.
Chemokine (C-C motif) ligand 25
C-C chemokine receptor type-9
Cluster of differentiation
Collagen type IIα1
Fluorescence-activated cell sorting
Mesenchymal stem cell
Polymerase chain reaction
SRY (sex-determining region Y)-box-9
transforming growth factor.
We thank Barbara Walewska and Anja Wachtel for excellent technical assistance. The study was supported by the Investitionsbank Berlin (IBB) and the European Regional Development Fund (grant number: 10147246), and the Berlin-Brandenburg Center for Regenerative Therapies (Bundesministerium für Bildung und Forschung, grant number: 1315848A). The grant sponsors had absolutely no influence on the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript to Stem Cells Research and Therapy.
- Kang SK, Shin IS, Ko MS, Jo JY, Ra JC: Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cells Int. 2012, 2012: 342968-PubMed CentralView ArticlePubMed
- Koelling S, Kruegel J, Irmer M, Path JR, Sadowski B, Miro X, Miosge N: Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell. 2009, 4: 324-335. 10.1016/j.stem.2009.01.015.View ArticlePubMed
- Langenbach F, Naujoks C, Kersten-Thiele PV, Berr K, Depprich RA, Kubler NR, Kogler G, Handschel J: Osteogenic differentiation influences stem cell migration out of scaffold-free microspheres. Tissue Eng Part A. 2010, 16: 759-766. 10.1089/ten.tea.2009.0131.View ArticlePubMed
- Pranav S, Kelber JA, Lee JW, Wright TN, Vecchio KS, Klemke RL, Chen SC: Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness. Biomaterials. 2012, 33: 7064-7070. 10.1016/j.biomaterials.2012.06.012.View Article
- Trouillas M, Prat M, Doucet C, Ernou I, Laplace-Builhe C, Blancard PS, Holy X, Lataillade JJ: A new platelet cryoprecipitate glue promoting bone formation after ectopic mesenchymal stromal cell-loaded biomaterial implantation in nude mice. Stem Cell Res Ther. 2013, 4: 1-10.1186/scrt149.PubMed CentralView ArticlePubMed
- Gurtner GC, Callaghan MJ, Longaker MT: Progress and potential for regenerative medicine. Annu Rev Med. 2007, 58: 299-312. 10.1146/annurev.med.58.082405.095329.View ArticlePubMed
- Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P: Bone marrow cells regenerate infarcted myocardium. Nature. 2001, 410: 701-705. 10.1038/35070587.View ArticlePubMed
- Strauer BE, Schannwell CM, Brehm M: Therapeutic potentials of stem cells in cardiac diseases. Minerva Cardioangiol. 2009, 57: 249-267.PubMed
- Mingliang R, Bo Z, Zhengguo W: Stem cells for cardiac repair: status, mechanisms, and new strategies. Stem Cells Int. 2011, 2011: 310928-PubMed CentralView ArticlePubMed
- Zakharova L, Mastroeni D, Mutlu N, Molina M, Goldman S, Diethrich E, Gaballa MA: Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc Res. 2010, 87: 40-49. 10.1093/cvr/cvq027.PubMed CentralView ArticlePubMed
- Kang KS, Kim SW, Oh YH, Yu JW, Kim KY, Park HK, Song CH, Han H: A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy. 2005, 7: 368-373. 10.1080/14653240500238160.View ArticlePubMed
- Liu W, Ren Y, Bossert A, Wang X, Dayawansa S, Tong J, He X, Smith DH, Gelbard HA, Huang JH: Allotransplanted neurons used to repair peripheral nerve injury do not elicit overt immunogenicity. PLoS One. 2012, 7: e31675-10.1371/journal.pone.0031675.PubMed CentralView ArticlePubMed
- Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D: Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med Hypotheses. 2008, 71: 900-908. 10.1016/j.mehy.2008.06.042.View ArticlePubMed
- Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H: Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med. 2007, 1: 74-79. 10.1002/term.8.View ArticlePubMed
- De Becker A, Van Hummelen P, Bakkus M, Broek IV, De Wever J, De Waele M, Van Riet I: Migration of culture-expanded human mesenchymal stem cells through bone marrow endothellum is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematol-Hematol J. 2007, 92: 440-449. 10.3324/haematol.10475.View Article
- Gutierrez-Fernandez M, Rodriguez-Frutos B, Ramos-Cejudo J, Teresa Vallejo-Cremades M, Fuentes B, Cerdan S, Diez-Tejedor E: Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke. Stem Cell Res Ther. 2013, 4: 11-10.1186/scrt159.PubMed CentralView ArticlePubMed
- Lee JW, Kim YH, Kim SH, Han SH, Hahn SB: Chondrogenic differentiation of mesenchymal stem cells and its clinical applications. Yonsei Med J. 2004, 45: 41-47.View ArticlePubMed
- Shekkeris AS, Jaiswal PK, Khan WS: Clinical applications of mesenchymal stem cells in the treatment of fracture non-union and bone defects. Curr Stem Cell Res Ther. 2012, 7: 127-133. 10.2174/157488812799218956.View ArticlePubMed
- Wang S, Qu X, Zhao RC: Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012, 5: 19-10.1186/1756-8722-5-19.PubMed CentralView ArticlePubMed
- Bhosale AM, Richardson JB: Articular cartilage: structure, injuries and review of management. Br Med Bull. 2008, 87: 77-95. 10.1093/bmb/ldn025.View ArticlePubMed
- O'Driscoll SW: The healing and regeneration of articular cartilage. J Bone Joint Surg Am. 1998, 80: 1795-1812.PubMed
- Tetteh ES, Bajaj S, Ghodadra NS: Basic science and surgical treatment options for articular cartilage injuries of the knee. J Orthop Sports Phys Ther. 2012, 42: 243-253. 10.2519/jospt.2012.3673.View ArticlePubMed
- Redman SN, Oldfield SF, Archer CW: Current strategies for articular cartilage repair. Eur Cell Mater. 2005, 9: 23-32. discussion 23–32PubMed
- Ringe J, Haupl T, Sittinger M: Future of tissue engineering in rheumatic diseases. Expert Opin Biol Ther. 2007, 7: 283-287. 10.1517/14712518.104.22.1683.View ArticlePubMed
- Ringe J, Sittinger M: Tissue engineering in the rheumatic diseases. Arthritis Res Ther. 2009, 11: 211-10.1186/ar2572.PubMed CentralView ArticlePubMed
- Ringe J, Burmester GR, Sittinger M: Regenerative medicine in rheumatic disease: progress in tissue engineering. Nat Rev Rheumatol. 2012, 8: 493-498. 10.1038/nrrheum.2012.98.View ArticlePubMed
- Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994, 331: 889-895. 10.1056/NEJM199410063311401.View ArticlePubMed
- Tang QO, Carasco CF, Gamie Z, Korres N, Mantalaris A, Tsiridis E: Preclinical and clinical data for the use of mesenchymal stem cells in articular cartilage tissue engineering. Expert Opin Biol Ther. 2012, 12: 1361-1382. 10.1517/14712598.2012.707182.View ArticlePubMed
- de la Fuente R, Abad JL, Garcia-Castro J, Fernandez-Miguel G, Petriz J, Rubio D, Vicario-Abejon C, Guillen P, Gonzalez MA, Bernad A: Dedifferentiated adult articular chondrocytes: a population of human multipotent primitive cells. Exp Cell Res. 2004, 297: 313-328. 10.1016/j.yexcr.2004.02.026.View ArticlePubMed
- Barbero A, Ploegert S, Heberer M, Martin I: Plasticity of clonal populations of dedifferentiated adult human articular chondrocytes. Arthritis Rheum. 2003, 48: 1315-1325. 10.1002/art.10950.View ArticlePubMed
- Lin L, Shen Q, Zhang C, Chen L, Yu C: Assessment of the profiling microRNA expression of differentiated and dedifferentiated human adult articular chondrocytes. J Orthop Res. 2011, 29: 1578-1584. 10.1002/jor.21423.View ArticlePubMed
- Morales TI: Chondrocyte moves: clever strategies?. Osteoarthritis Cartilage. 2007, 15: 861-871. 10.1016/j.joca.2007.02.022.PubMed CentralView ArticlePubMed
- Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M: Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem. 2007, 101: 135-146. 10.1002/jcb.21172.View ArticlePubMed
- Hara Y, Stolk M, Ringe J, Dehne T, Ladhoff J, Kotsch K, Reutzel-Selke A, Reinke P, Volk HD, Seifert M: In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transpl Int. 2011, 24: 1112-1123. 10.1111/j.1432-2277.2011.01328.x.View ArticlePubMed
- Orbay H, Tobita M, Mizuno H: Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int. 2012, 2012: 461718-PubMed CentralView ArticlePubMed
- Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH: Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010, 38: 1110-1116. 10.1177/0363546509359067.View ArticlePubMed
- Dhinsa BS, Adesida AB: Current clinical therapies for cartilage repair, their limitation and the role of stem cells. Curr Stem Cell Res Ther. 2012, 7: 143-148. 10.2174/157488812799219009.View ArticlePubMed
- Kamei G, Kobayashi T, Ohkawa S, Kongcharoensombat W, Adachi N, Takazawa K, Shibuya H, Deie M, Hattori K, Goldberg JL, Ochi M: Articular cartilage repair with magnetic mesenchymal stem cells. Am J Sports Med. 2013, 41: 1255-1264. 10.1177/0363546513483270.View ArticlePubMed
- Kalwitz G, Andreas K, Endres M, Neumann K, Notter M, Ringe J, Sittinger M, Kaps C: Chemokine profile of human serum from whole blood: migratory effects of CXCL-10 and CXCL-11 on human mesenchymal stem cells. Connect Tissue Res. 2010, 51: 113-122. 10.3109/03008200903111906.View ArticlePubMed
- Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS: The human serum metabolome. PLoS One. 2011, 6: e16957-10.1371/journal.pone.0016957.PubMed CentralView ArticlePubMed
- Rajala K, Lindroos B, Hussein SM, Lappalainen RS, Pekkanen-Mattila M, Inzunza J, Rozell B, Miettinen S, Narkilahti S, Kerkelä E, Aalto-Setälä K, Otonkoski T, Suuronen R, Hovatta O, Skottman H: A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells. PLoS One. 2010, 5: e10246-10.1371/journal.pone.0010246.PubMed CentralView ArticlePubMed
- Mannello F, Tonti GA: Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!. Stem Cells. 2007, 25: 1603-1609. 10.1634/stemcells.2007-0127.View ArticlePubMed
- Christopherson K, Hromas R: Chemokine regulation of normal and pathologic immune responses. Stem Cells. 2001, 19: 388-396. 10.1634/stemcells.19-5-388.View ArticlePubMed
- Endres M, Andreas K, Kalwitz G, Freymann U, Neumann K, Ringe J, Sittinger M, Haupl T, Kaps C: Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells. Osteoarthritis Cartilage. 2010, 18: 1458-1466. 10.1016/j.joca.2010.08.003.View ArticlePubMed
- Parmo-Cabanas M, Garcia-Bernal D, Garcia-Verdugo R, Kremer L, Marquez G, Teixido J: Intracellular signaling required for CCL25-stimulated T cell adhesion mediated by the integrin alpha4beta1. J Leukoc Biol. 2007, 82: 380-391. 10.1189/jlb.1206726.View ArticlePubMed
- Liu Z, Klominek J: Chemotaxis and chemokinesis of malignant mesothelioma cells to multiple growth factors. Anticancer Res. 2004, 24: 1625-1630.PubMed
- Vertelov G, Kharazi L, Muralidhar MG, Sanati G, Tankovich T, Kharazi A: High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA. Stem Cell Res Ther. 2013, 4: 5-10.1186/scrt153.PubMed CentralView ArticlePubMed
- Raheja LF, Genetos DC, Wong A, Yellowley CE: Hypoxic regulation of mesenchymal stem cell migration: the role of RhoA and HIF-1alpha. Cell Biol Int. 2011, 35: 981-989. 10.1042/CBI20100733.View ArticlePubMed
- Seton-Rogers S: Cytokine cues. Nat Rev Cancer. 2011, 11: 690-View ArticlePubMed
- Silva TA, Garlet GP, Fukada SY, Silva JS, Cunha FQ: Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J Dent Res. 2007, 86: 306-319. 10.1177/154405910708600403.View ArticlePubMed
- Baggiolini M, Dahinden CA: Cc-chemokines in allergic inflammation. Immunol Today. 1994, 15: 127-133. 10.1016/0167-5699(94)90156-2.View ArticlePubMed
- Penido C, Costa MFS, Souza MC, Costa KA, Candea ALP, Benjamim CF, Henriques MDMO: Involvement of CC chemokines in gamma delta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway. Int Immunol. 2008, 20: 129-139. 10.1093/intimm/dxm128.View ArticlePubMed
- Gonzalo JA, Lloyd CM, Wen DY, Albar JP, Wells TNC, Proudfoot A, Martinez C, Dorf M, Bjerke T, Coyle AJ, Gutierrez-Ramos JC: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med. 1998, 188: 157-167. 10.1084/jem.188.1.157.PubMed CentralView ArticlePubMed
- Stich S, Loch A, Leinhase I, Neumann K, Kaps C, Sittinger M, Ringe J: Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. Eur J Cell Biol. 2008, 87: 365-376. 10.1016/j.ejcb.2008.03.009.View ArticlePubMed
- Phinney DG, Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair: current views. Stem Cells. 2007, 25: 2896-2902. 10.1634/stemcells.2007-0637.View ArticlePubMed
- Binger T, Stich S, Andreas K, Kaps C, Sezer O, Notter M, Sittinger M, Ringe J: Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25. Exp Cell Res. 2009, 315: 1468-1479. 10.1016/j.yexcr.2008.12.022.View ArticlePubMed
- Meurens F, Whale J, Brownlie R, Dybvig T, Thompson DR, Gerdts V: Expression of mucosal chemokines TECK/CCL25 and MEC/CCL28 during fetal development of the ovine mucosal immune system. Immunology. 2007, 120: 544-555. 10.1111/j.1365-2567.2006.02532.x.PubMed CentralView ArticlePubMed
- Meurens F, Berri M, Whale J, Dybvig T, Strom S, Thompson D, Brownlie R, Townsend HG, Salmon H, Gerdts V: Expression of TECK/CCL25 and MEC/CCL28 chemokines and their respective receptors CCR9 and CCR10 in porcine mucosal tissues. Vet Immunol Immunopathol. 2006, 113: 313-327. 10.1016/j.vetimm.2006.05.014.View ArticlePubMed
- Ullah M, Hamouda H, Stich S, Sittinger M, Ringe J: A reliable protocol for the isolation of viable, chondrogenically differentiated human mesenchymal stem cells from high-density pellet cultures. BioRes Open Access. 2012, 1: 297-305. 10.1089/biores.2012.0279.PubMed CentralView ArticlePubMed
- Stich S, Haag M, Haupl T, Sezer O, Notter M, Kaps C, Sittinger M, Ringe J: Gene expression profiling of human mesenchymal stem cells chemotactically induced with CXCL12. Cell Tissue Res. 2009, 336: 225-236. 10.1007/s00441-009-0768-z.View ArticlePubMed
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29: e45-10.1093/nar/29.9.e45.PubMed CentralView ArticlePubMed
- Ullah M, Stich S, Notter M, Eucker J, Sittinger M, Ringe J: Transdifferentiation of mesenchymal stem cells-derived adipogenic-differentiated cells into osteogenic- or chondrogenic-differentiated cells proceeds via dedifferentiation and has a correlation with cell cycle arresting and driving genes. Differentiation. 2013, 85: 78-90. 10.1016/j.diff.2013.02.001.View ArticlePubMed
- Vicari AP, Figueroa DJ, Hedrick JA, Foster JS, Singh KP, Menon S, Copeland NG, Gilbert DJ, Jenkins NA, Bacon KB, Zlotnik A: TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity. 1997, 7: 291-301. 10.1016/S1074-7613(00)80531-2.View ArticlePubMed
- Wurbel MA, McIntire MG, Dwyer P, Fiebiger E: CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One. 2011, 6: e16442-10.1371/journal.pone.0016442.PubMed CentralView ArticlePubMed
- Lee HJ, Choi BH, Min BH, Park SR: Changes in surface markers of human mesenchymal stem cells during the chondrogenic differentiation and dedifferentiation processes in vitro. Arthritis Rheum. 2009, 60: 2325-2332. 10.1002/art.24786.View ArticlePubMed
- Chang CB, Han SA, Kim EM, Lee S, Seong SC, Lee MC: Chondrogenic potentials of human synovium-derived cells sorted by specific surface markers. Osteoarthritis Cartilage. 2013, 21: 190-199. 10.1016/j.joca.2012.10.005.View ArticlePubMed
- Lu YL, Dhanaraj S, Wang ZW, Bradley DM, Bowman SM, Cole BJ, Binette F: Minced cartilage without cell culture serves as an effective intraoperative cell source for cartilage repair. J Orthop Res. 2006, 24: 1261-1270. 10.1002/jor.20135.View ArticlePubMed
- Kouri JB, Jimenez SA, Quintero M, Chico A: Ultrastructural study of chondrocytes from fibrillated and non-fibrillated human osteoarthritic cartilage. Osteoarthr Cartilage. 1996, 4: 111-125. 10.1016/S1063-4584(05)80320-6.View Article
- Qiu W, Murray MM, Shortkroff S, Lee CR, Martin SD, Spector M: Outgrowth of chondrocytes from human articular cartilage explants and expression of alpha-smooth muscle actin. Wound Repair Regen. 2000, 8: 383-391. 10.1111/j.1524-475X.2000.00383.x.View ArticlePubMed
- Maumus M, Guerit D, Toupet K, Jorgensen C, Noel D: Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther. 2011, 2: 14-10.1186/scrt55.PubMed CentralView ArticlePubMed
- Mortier A, Gouwy M, Van Damme J, Proost P: Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res. 2011, 317: 642-654. 10.1016/j.yexcr.2010.11.016.View ArticlePubMed
- Hoffmann R: Using the iHOP information resource to mine the biomedical literature on genes, proteins, and chemical compounds. Curr Protoc Bioinformatics. 2007, Chapter 1: Unit1 16-PubMed
- Balcells I, Cirera S, Busk PK: Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol. 2011, 11: 70-10.1186/1472-6750-11-70.PubMed CentralView ArticlePubMed
- Karrer EE, Lincoln JE, Hogenhout S, Bennett AB, Bostock RM, Martineau B, Lucas WJ, Gilchrist DG, Alexander D: In situ isolation of mRNA from individual plant cells: creation of cell-specific cDNA libraries. Proc Natl Acad Sci USA. 1995, 92: 3814-3818. 10.1073/pnas.92.9.3814.PubMed CentralView ArticlePubMed
- Van Linthout S, Stamm C, Schultheiss HP, Tschope C: Mesenchymal stem cells and inflammatory cardiomyopathy: cardiac homing and beyond. Cardiol Res Pract. 2011, 2011: 757154-PubMed CentralPubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.